Prasugrel: Additional Phase III data

A subgroup analysis of 2,943 patients tested for the C3435T variant in the P glycoprotein ( MDR1; ABCB1; P-gp; CD243) gene in the Phase III TRITON-TIMI 38 trial showed that patients treated with Plavix clopidogrel who had two C3435T variants had a significantly higher rate of the composite incidence of cardiovascular death, non-fatal heart attack and non-fatal stroke vs. Plavix-treated patients without the variant (12.9% vs. 8.2%, p=0.033). In contrast, patients treated with Effient who had two C3435T variants did not have a significantly higher rate of the composite endpoint vs. Effient-treated patients without the variant (11% vs. 9.7%, p=0.64). Data were presented at the American College of Cardiology meeting in Atlanta. ...